Arrow Greentech Ltd

₹ 865 1.07%

01 Oct - close price

arrowgreentech.com BSE: 516064 NSE: ARROWGREEN

About

Incorporated in 1982, Arrow Greentech
Ltd is in the business of bio-degradable (green) products, high-tech products and having Patents income for such products /technology^[1]

Key Points

Business Overview:^[1]^[2]
AGL is India’s largest manufacturer of water-soluble films, specializing in the development, production, and marketing of a diverse range of PVA/PVOH-based films. Its portfolio includes innovative applications such as mouth dissolving strips for pharmaceutical and nutraceutical use. In addition to green packaging solutions, AGL also offers advanced security products and intellectual property services, positioning itself as a multi-vertical technology-driven company.

Website BSE NSE

Market Cap ₹ 1,305 Cr.
Current Price ₹ 865
High / Low ₹ 953 / 342
Stock P/E 20.4
Book Value ₹ 155
Dividend Yield 0.58 %
ROCE 29.6 %
ROE 21.2 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company is almost debt free.
Company is expected to give good quarter
Company has delivered good profit growth of 49.4% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 28.2%
Promoter holding has increased by 0.82% over last quarter.

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Industrials Capital Goods Industrial Products Packaging

Part of BSE Industrials

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	44	29	25	51	66	65	55	57	42	61	56	42	88
	29	20	18	35	38	39	37	41	27	40	37	31	52
Operating Profit	14	9	7	16	28	26	18	16	14	21	19	10	36
OPM %	33%	31%	29%	31%	42%	41%	33%	28%	34%	34%	34%	25%	41%
	1	1	1	1	1	1	2	2	2	2	2	2	2
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	2	2	2	2	2	2	2	2	2	2	2	2	2
Profit before tax	13	8	6	14	27	26	18	16	14	21	19	11	36
Tax %	30%	33%	15%	29%	26%	28%	27%	28%	23%	24%	31%	30%	24%
	9	5	5	10	20	19	13	11	11	16	13	7	27
EPS in Rs	6.19	3.38	3.25	6.71	13.36	12.37	8.52	7.58	7.22	10.43	8.82	4.90	18.15
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	49	51	53	35	34	22	52	34	109	149	243	201	247
	19	14	16	29	49	29	44	41	85	102	155	136	160
Operating Profit	29	37	36	5	-14	-7	9	-7	24	47	89	65	86
OPM %	60%	73%	69%	16%	-42%	-34%	17%	-21%	22%	31%	36%	32%	35%
	1	5	5	2	1	1	2	2	2	3	5	9	9
Interest	-0	-0	0	0	0	1	1	1	1	1	0	1	0
Depreciation	1	1	2	4	4	4	5	5	7	8	7	8	8
Profit before tax	30	41	39	3	-17	-10	6	-11	18	41	86	65	87
Tax %	22%	24%	12%	95%	-1%	-2%	-22%	-16%	32%	28%	27%	27%
	22	31	35	0	-17	-10	7	-9	12	29	63	47	64
EPS in Rs	15.84	21.67	24.19	0.19	-11.83	-7.07	4.55	-6.62	8.14	19.56	41.84	31.38	42.30
Dividend Payout %	13%	17%	19%	870%	-4%	-0%	-0%	-0%	12%	10%	10%	16%

Compounded Sales Growth
10 Years:	15%
5 Years:	31%
3 Years:	23%
TTM:	13%

Compounded Profit Growth
10 Years:	4%
5 Years:	49%
3 Years:	54%
TTM:	19%

Stock Price CAGR
10 Years:	6%
5 Years:	49%
3 Years:	32%
1 Year:	51%

Return on Equity
10 Years:	14%
5 Years:	21%
3 Years:	28%
Last Year:	21%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	12	12	12	12	12	14	14	14	15	15	15	15
Reserves	35	58	86	86	66	62	70	61	83	112	173	219
	0	0	0	0	0	5	5	5	3	1	1	2
	13	16	8	8	9	10	9	9	20	17	19	19
Total Liabilities	60	86	106	106	87	92	99	89	121	145	208	256
	11	16	26	26	23	28	26	28	37	37	38	37
CWIP	1	1	1	1	2	10	12	13	1	3	2	2
Investments	15	15	18	29	17	14	9	1	0	0	46	77
	33	53	60	49	45	40	53	46	83	104	123	141
Total Assets	60	86	106	106	87	92	99	89	121	145	208	256

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	26	27	17	5	-16	3	1	2	3	18	68	43
	-11	-6	-12	-13	8	-24	2	-2	-14	-14	-55	-26
	-4	-7	-2	-6	-3	12	-2	-2	8	-4	-4	-7
Net Cash Flow	11	14	2	-14	-11	-8	2	-1	-3	1	9	10
Free Cash Flow	22	21	4	2	-23	-15	-4	-6	-1	8	61	39
CFO/OP	107%	94%	78%	159%	109%	-53%	17%	-33%	25%	71%	103%	94%

Ratios

Consolidated / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	4	40	66	84	81	56	49	40	88	79	44	62
Inventory Days	78		229	204	84	99	51	127	101	138	66	101
Days Payable	153		267	111	49	80	27	60	68	31	29	22
Cash Conversion Cycle	-71	40	28	178	116	75	73	106	121	187	81	141
Working Capital Days	-68	-35	57	119	116	59	95	112	104	117	70	100
ROCE %	76%	69%	46%	3%	-19%	-12%	7%	-12%	21%	35%	53%	30%

Insights

In beta

Mar 2016

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Granted Patents (In-force)
count

xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
						xx	xx	xx	xx
						xx	xx	xx	xx
						xx	xx	xx	xx
						xx	xx	xx	xx

Please log in to see hidden values.

Avery Pharma FSSAI Approved Products
count

Avery Pharma RX (Prescription) Approved Products
count

Patent Applications in Process (Total)
count

Registered Trademarks
count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	68.60%	68.60%	68.60%	68.60%	66.75%	64.81%	64.81%	64.81%	64.81%	64.81%	64.83%	65.65%
	0.02%	0.00%	1.28%	0.21%	0.09%	0.56%	0.27%	0.25%	0.12%	0.14%	0.06%	0.20%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.04%	0.11%	0.69%	0.79%	0.82%	0.99%
	31.38%	31.42%	30.13%	31.19%	33.16%	34.63%	34.88%	34.84%	34.38%	34.25%	34.28%	33.16%
No. of Shareholders	8,137	12,630	13,430	14,838	22,320	22,038	22,605	21,685	21,947	21,521	21,442	20,487

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Jun 2026
	69.68%	65.42%	65.42%	70.35%	70.28%	70.35%	68.60%	68.60%	64.81%	64.83%	65.65%
	0.80%	1.30%	0.83%	0.10%	0.21%	0.00%	0.13%	1.28%	0.27%	0.06%	0.20%
	0.35%	8.16%	1.95%	0.14%	0.00%	0.00%	0.00%	0.00%	0.04%	0.82%	0.99%
	29.18%	25.12%	31.80%	29.41%	29.52%	29.65%	31.28%	30.13%	34.88%	34.28%	33.16%
No. of Shareholders	5,981	8,578	9,402	8,595	7,638	8,934	7,760	13,430	22,605	21,442	20,487

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Right Issue

Concalls

Aug 2026

Transcript

AI Summary
PPT
May 2026

Transcript

AI Summary
PPT
Feb 2026

Transcript

AI Summary
PPT
Nov 2025

Transcript

AI Summary
PPT
Aug 2025

Transcript

AI Summary
PPT
May 2025

Transcript

AI Summary
PPT
Feb 2025

Transcript

AI Summary
PPT
Oct 2024

Transcript

AI Summary
PPT
May 2024

Transcript

AI Summary
PPT
May 2024

Transcript

AI Summary
PPT
May 2024

Transcript

AI Summary
PPT
Feb 2024

Transcript

AI Summary
PPT
Nov 2023

Transcript

AI Summary
PPT
Jun 2023

Transcript

AI Summary
PPT
Nov 2019

Transcript

AI Summary
PPT
Feb 2019

Transcript

AI Summary
PPT
Aug 2016

Transcript

AI Summary
PPT
May 2016

Transcript

AI Summary
PPT
Nov 2015

Transcript

AI Summary
PPT
Aug 2015

Transcript

AI Summary
PPT